Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somatrogon weekly vs daily Genotropin in children with SGA or ISS
2025-523832-38-00Phase 3Authorised
- Sponsor
- Schneider Children's Medical Center of Israel
- Start
- Sep 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, randomised trial of somatrogon in Small for gestational age (SGA) and Idiopathic Short Stature (ISS) (2 arms), sponsored by Schneider Children's Medical Center of Israel. Primary endpoint: Annualized height velocity at 12 months. Planned start Sep 2026; status: authorised.
02
Drugs
somatrogon
03
Conditions
Small for gestational age (SGA)Idiopathic Short Stature (ISS)
Beyond the preview
Go deeper on 2025-523832-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523832-38-00.